Behavioral Neuropharmacology and Neuroimaging Laboratory on Addictions, Clinical Research Institute on Addictions, Department of Pharmacology and Toxicology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA.
Behavioral Neuropharmacology and Neuroimaging Laboratory on Addictions, Clinical Research Institute on Addictions, Department of Pharmacology and Toxicology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA; Department of Psychology, University at Buffalo, Buffalo, NY, USA.
Life Sci. 2021 Jan 1;264:118708. doi: 10.1016/j.lfs.2020.118708. Epub 2020 Nov 10.
Examine the effects of chronic oral Methylphenidate (MP) treatment on the N-Methyl-D-aspartic acid (NMDA) glutamate receptor binding in the rat brain using a previously established drinking paradigm that has been shown to deliver MP with similar pharmacokinetic profile as observed clinically.
Briefly, rats were divided into three treatment groups of water, low dose MP (LD; 4/10 mg/kg), or high dose MP (HD; 30/60 mg/kg). Following a 3-month treatment period, some rats were sacrificed while others went through an additional 1-month abstinence period before they were sacrificed. In vitro autoradiography (ARG) was carried out using [H] MK801 to examine NMDA receptor binding in the brain.
The dose-dependent effects of MP following 13 weeks of treatment on [H] MK-801 binding were seen across the brain in the following regions: prelimbic, insular, secondary motor, primary motor, retrosplenial, rhinal, piriform, auditory, visual, dorsolateral striatum, nucleus accumbens core, hippocampus, amygdala, and thalamic regions. No differences were observed in [H] MK-801 binding levels in animals that underwent the same treatment followed by a 4 week abstinence.
These results demonstrate that chronic MP treatment altered NMDA receptor expression throughout the brain, which in turn may impact an individual's drug-seeking behavior, fear memory formation and overall activity. However, these effects of chronic MP were eliminated following cessation of treatment.
通过先前建立的一种已被证明能以与临床观察到的相似药代动力学特征给予 MP 的饮水范式,研究慢性口服哌醋甲酯(MP)治疗对大鼠大脑中 N-甲基-D-天冬氨酸(NMDA)谷氨酸受体结合的影响。
简要地说,将大鼠分为三组,分别为水组、低剂量 MP(LD;4/10mg/kg)组或高剂量 MP(HD;30/60mg/kg)组。经过 3 个月的治疗期后,一部分大鼠被处死,而另一部分则在另外 1 个月的戒断期后被处死。使用 [H]MK801 进行体外放射自显影(ARG),以检查大脑中的 NMDA 受体结合。
在 13 周的治疗后,MP 呈现出剂量依赖性效应,对 [H]MK-801 结合的影响在大脑的以下区域可见:额前皮质、岛叶皮质、次级运动皮质、初级运动皮质、后扣带回皮质、梨状皮质、嗅球、视皮质、背外侧纹状体、伏隔核核心、海马、杏仁核和丘脑区域。在接受相同治疗后进行 4 周戒断的动物中,[H]MK-801 结合水平没有差异。
这些结果表明,慢性 MP 治疗改变了大脑中 NMDA 受体的表达,这反过来可能会影响个体的觅药行为、恐惧记忆形成和整体活动。然而,在停止治疗后,慢性 MP 的这些影响被消除。